APA (7th ed.) Citation

Li, R., Wen, X., Lv, R., Ren, X., Cheng, B., Wang, Y., . . . Tang, X. (2024). DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma. Cellular Oncology (2211-3428), 47(4), 1129. https://doi.org/10.1007/s13402-024-00917-x

Chicago Style (17th ed.) Citation

Li, Rui, Xin Wen, Ru-xue Lv, Xian-yue Ren, Bing-lin Cheng, Yi-kai Wang, Ru-zhen Chen, Wen Hu, and Xin-Ran Tang. "DNA-methylome-derived Epigenetic Fingerprint as an Immunophenotype Indicator of Durable Clinical Immunotherapeutic Benefits in Head and Neck Squamous Cell Carcinoma." Cellular Oncology (2211-3428) 47, no. 4 (2024): 1129. https://doi.org/10.1007/s13402-024-00917-x.

MLA (9th ed.) Citation

Li, Rui, et al. "DNA-methylome-derived Epigenetic Fingerprint as an Immunophenotype Indicator of Durable Clinical Immunotherapeutic Benefits in Head and Neck Squamous Cell Carcinoma." Cellular Oncology (2211-3428), vol. 47, no. 4, 2024, p. 1129, https://doi.org/10.1007/s13402-024-00917-x.